A lively dialectic between proponents of bacterial and viral aetiologies may generate useful hypotheses to be criticised and tested during the next exciting years of research into diarrhoeal diseases.

NORMAN R GRIST
C R MADELEY

University Department of Infectious Diseases,
Ruchill Hospital,
Glasgow

Multicentre trial of prednisolone in the Guillain-Barré syndrome

SIR,—The Guillain-Barré syndrome, discussed in your leading article (26 July, p 190), has a misleading reputation as a benign condition. Severe weakness lasts for at least three months in most patients and respiratory failure necessitates artificial ventilation in about 20%. Despite intensive care mortality rates of 5 to 10% are still found in most modern series and recovery is incomplete in a further 5 to 10%.¹⁻³ Accordingly the potential benefits of an agent such as prednisolone are worth investigating.

Sadly, after quarter of a century of uncontrolled trials the role of corticosteroids in the treatment of Guillain-Barré syndrome remains controversial.³⁻⁵ We are therefore engaged in a multicentre controlled trial in which the results of randomly allocated treatment with or without a course of prednisolone are being assessed by "blind" observers. The trial is now in its second year and 20 patients have entered. Preliminary statistical analysis of our results by Professor P Armitage does not reveal an advantage to either group. We estimate that 50 patients will be required to show a clinically worthwhile change due to treatment. Patients from any hospital in London or its immediate neighbourhood are eligible for entry to the trial, and further details can be obtained from us.

R A C HUGHES

Guy's Hospital,
London SE1

G D PERKIN
G M STERN

University College Hospital,
London WC1

J NEWSOM DAVIS

National Hospital,
Queen Square,
London WC1

P K THOMAS

Royal Free Hospital,
London NW3

- 1 Masucci, E F, and Kurtzke, J F, *Journal of Neurological Sciences*, 1971, 13, 483.
- 2 Marshall, J, *Brain*, 1963, 86, 55.
- 3 Goodall, J A D, Kosmidis, J C, and Geddes, A M, *Lancet*, 1974, 1, 524.
- 4 Princeas, J, *Acta Neurologica Scandinavica*, 1970, 46, Supplement 44, 1.
- 5 Bammer, H, and Schaltenbrand, G, *Münchener medizinische Wochenschrift*, 1965, 107, 1629.

SI units

SIR,—Since my letter (19 July, p 159) on the subject of SI units, I noted that there was no further correspondence from any clinician who could point to any advantage resulting from their use.

At the insistence of my medical colleagues, I carried out a survey of all the medical staff in our health district, and the results indicate that, out of a possible 150 ballot papers, there were 90 signed objections to the introduction of SI. There was one dissenting colleague.

As I mentioned in my previous letter, I would be extremely foolish to force a system of clinical reporting on my colleagues who did not desire it, and I must say that the dilemma remains unresolved, especially in the light of Ministry "advice."

I find none of the arguments advanced in favour of SI as being convincing, and I know that medical staff and others make frequent use of literature derived from America and other foreign sources, which so far will continue to report in "proper metricated" units. It is easy to say that "everybody else is out of step but me," but in this instance everybody else—that is, the world—will be in step while the United Kingdom, by virtue of SI adoption, will be talking a curious scientific jargon almost singular in world clinical medicine.

MICHAEL P WALSH

Pathology Department,
Peterborough District Hospital,
Peterborough

SIR,—The King's Lynn District Hospital Medical Staff Committee approved on 23 October the following motion: "That we do not intend to introduce SI units on 31 December 1975."

The staff suspected that support for the change is rather less strong than advocates of the new régime would have us believe.

MICHAEL J BRINDLE
Chairman,
King's Lynn District
Hospital Medical Staff Committee

King's Lynn, Norfolk

Influenza vaccination

SIR,—I read with great interest your leading article on influenza vaccination (18 October, p 125) and would like to make some comments supported by evidence which may not have been in your possession.

It is stated that field evidence of the protective effect of a live attenuated influenza vaccine given intranasally is still lacking. As this is a product very recently introduced into the UK this is so of this country, but a considerable amount of such work has been done on the Continent and in the USA.

To the best of our knowledge there is no field evidence of the protective effect of any updated inactivated vaccines against the A/Scotland strain. The killed vaccine has been shown to produce a better antibody response in general, but there is often a poor correlation between serum antibody response and the protection afforded an individual against influenza following vaccination. Protection of between 70 and 80% with reasonable certainty is claimed in your article for inactivated vaccine. However, a recent study has shown over 80% protection against natural challenge with A/Port Chalmers using a live vaccine.¹ Response to the A/Scotland virus is stated to be unlikely to be as good in the case of a live vaccine as that provoked by a killed vaccine, but again recent work has shown a serum conversion rate of 84% to this virus using a live vaccine.² Postvaccination titres were as high to A/Scotland as to A/Port Chalmers and the homologous strain.

A small point of correction is that the work by Lauteria *et al* referred to in your article involved an early strain of live attenuated virus "Ann," not the one currently available ("Alice").

The slight adverse effect on small-airway function observed in healthy volunteers³ has not been confirmed in a further study in the USA in which changes in pulmonary function (using flow volume curves with air and helium mixture) have been used in both asthmatics and a control group. No changes in pulmonary function were demonstrated, no significant symptoms were reported, and a fourfold rise in antibody titre was found in persons with low titres.⁴

In conclusion, it is submitted that live attenuated influenza vaccine has been well tolerated by over 10 000 people during its development, subsequently by well over a quarter of a million in clinical usage, and significantly by 381 patients who took part in clinical trials and were suffering from bronchopulmonary disease—that is, the high-risk groups.

E M JACKSON-MOORE
Medical Director,
Smith, Kline and French Laboratories Ltd

Welwyn Garden City, Herts

- 1 Douglas, G, as reported by A Prinzie at a symposium at the Royal Society of Medicine, London, April 1975.
- 2 Kuwert, E, in Symposium on Viral Diseases, Vienna, September 1975.
- 3 Rosenzweig, D Y, *et al*, *American Review of Respiratory Diseases*, 1975, 111, 399.
- 4 Storms, W W, *et al*. Submitted for publication.

** We are familiar with published, and much unpublished, work on live attenuated influenza vaccine from both the Continent and the USA, including that presented at the London symposium to which Dr Jackson-Moore refers. We reaffirm our view that although "there are expectations that live vaccines will stimulate a more solid immunity than killed," so far there have been no unequivocal reports that the live A/England vaccine protects against clinical infection with homologous or related viruses.

We agree that there is no field evidence so far available of the protective effect of up-to-date inactivated vaccine against the A/Scotland strain of influenza A virus. At the same time most workers in the field, including manufacturers, would expect that inactivated A/Scotland vaccine should be as protective against the homologous virus as previous inactivated vaccines against their homologous viruses. This expectation underlies the regular updating of inactivated vaccines, a policy that has not yet been doubted.

It is encouraging that "Alice" live A/England vaccine may give a serum conversion rate of 84% against the A/Scotland virus. Nevertheless, the serum conversion rate is only one criterion of the antibody response, and in the study to which Dr Jackson-Moore refers Professor Kuwert also reported that the serum HI antibody titres were lower after live virus vaccine than after inactivated vaccine. He further reported that the local HI antibody response was predominantly strain-specific.

That live vaccine may have an adverse effect on small-airway function is a possibility that it would be unwise entirely to disregard on the basis of the two negative reports. It is greatly hoped that live attenuated influenza vaccines will prove to be

as safe as Dr Jackson-Moore believes them to be; they undoubtedly have great promise. Nevertheless, at the present time we would recommend for at-risk patients an up-to-date inactivated vaccine rather than live A/England vaccine.—ED, *BMJ*.

Thrombocytopenia during treatment with clonazepam

SIR,—We think it is desirable to publicise as a matter of some urgency a potentially dangerous thrombocytopenia developing probably as a reaction to the drug clonazepam (Rivotril).

The patient is a 52-year-old woman resident at a hostel for mentally subnormal women under the control of Botleys Park Hospital. She has an IQ of 55 and is able to carry on a useful conversation. There is a history of head injury at age 3 followed by epilepsy. There is no reliable history of her development before that. Until recently she had no epilepsy after childhood.

On 25 September 1974 while drinking morning tea at work she was noticed to be oblivious of her surroundings; her right hand was shaking and she was spilling her tea. She recovered completely in a few seconds. She had a similar attack the next day, another in October, and one in November. Investigations including blood glucose and calcium, lumbar puncture, and electroencephalography were negative. She was free of attacks until June 1975, when treatment with phenytoin 150 mg daily was started. She had further attacks and clonazepam 0.5 mg twice daily was added on 30 July. Following a further attack in August this was increased to 1.0 mg twice daily. On 5 September she had a mild epistaxis and two days later more severe epistaxis and purpura. She was admitted to St Peter's Hospital, where her nostrils were found to be blocked with clotted blood and she was bleeding from the lower gum, the upper being edentulous. Multiple purpuric spots and bruises were present on both legs. All drugs were stopped.

Examination of the blood showed a platelet count of $6 \times 10^9/l$ (6000/mm³), but was otherwise normal. A sternal marrow puncture the following day showed an excess of megakaryocytes and no other abnormality. Prednisone 20 mg three times a day was started. The puncture site continued to ooze for 2-3 days. Platelet counts performed on 8 and 10 September showed a fall to less than $1 \times 10^9/l$ (1000/mm³).

On 12 September the patient had a grand mal fit and was started on phenobarbitone 30 mg three times a day. On 19 September the platelet count had risen to $48 \times 10^9/l$ (48 000/mm³) and it was $64 \times 10^9/l$ (64 000/mm³) on 22 September and $152 \times 10^9/l$ (152 000/mm³) on 10 October. She is being followed up and her steroids will be reduced and stopped if she has no relapse.

There have been only two reports of thrombocytopenia attributed to phenytoin, although it is prescribed about a million times a year. No warning is given about thrombocytopenia as a reaction to clonazepam by the manufacturers (Roche). As a result of inquiries they have kindly searched the literature and have found one report by Girke *et al*¹ of a fall in the thrombocyte count in 9 of 26 patients being treated with clonazepam alone, with a minimum value of $90 \times 10^9/l$ (90 000/mm³). These changes were shown "to be reversible at check-ups." It is not stated how the changes were reversed.

The Committee on Safety of Medicines has been informed.

R M VEALL

Botleys Park Hospital

H C HOGARTH

St Peter's Hospital,
Chertsey, Surrey

¹ Girke, W, Krebs, F A, and Lenzner, W, *Ärztliche Praxis*, 1973, 25, 4518, 4520, 4522.

Treatment of meningitis and encephalitis

SIR,—I would question Dr C C Smith's choice of cephaloridine for treatment of penicillin-allergic patients with meningococcal infection (8 November, p 335). The organism can be relatively resistant to cephalosporins and there have been reports of poor clinical results of treatment with both cephaloridine¹ and cephalothin.² Furthermore, one needs to remember that cross-allergenicity does exist between the cephalosporins and the penicillins; from the worldwide clinical experience of using cephalosporins in penicillin-allergic patients the estimated risk of clinical reaction has been stated to be about 6-9%.³

As things stand at present the choice of drug in such cases should be chloramphenicol, although co-trimoxazole may turn out to be a safer alternative if the encouraging results from Africa⁴ can be confirmed in further studies.

B K MANDAL

Monsall Hospital,
Manchester

¹ McKenzie, P, *et al*, *Postgraduate Medical Journal*, 1967, 43, suppl (August), p 142.

² Southern, P M, and Sandford, J P, *New England Journal of Medicine*, 1969, 280, 1163.

³ Dash, C H, *Journal of Antimicrobial Chemistry and Chemotherapy*, 1975, 1, suppl, p 107.

⁴ Felix, H, *Revue de Médecine*, 1971, 23, 1503.

Abortion again

SIR,—In your leading article on abortion (1 November, p 244) you fail to discuss the most important principle—that the fetus is a human being—and its corollary—that its life should not be destroyed except to save the mother's life. Your underlying principle seems to be that abortion on demand is desirable, and I think it only fair that you give space in your columns for those opposing this view to state their case.

There are many doctors who treat the fetus as a human being who has as much right to our medical skills as any other person and who is not to be treated like a cancer, to be cut out and thrown away.

IAN EVANS

Swansea

Hazard of air embolism with multiple infusion apparatus

SIR,—In their short report (25 October, p 204) Dr R V Heatley and Mr B K Evans describe an apparatus designed to overcome the problem of multiple intravenous fluid infusion. When similarly trying to simplify the "plumbing" of just such regimens by utilising a common drip chamber and regulating the flow from each container by clamps above that chamber I have found experimentally that there is a serious risk of air embolism, whether or not a pump is used, if the drip chamber is at a height above that of the central venous pressure. If one bottle empties unobserved free entry of air to the common drip chamber will occur via that bottle's airway. The fluid level will then drop repeatedly into the line to the patient while the other drips continue, so that a flowing column of fluid and air enters the circulation. The higher the chamber, the faster the inflow. The fact that fluid from the other bottles continues to drip into the

chamber increases the likelihood that the attendant will fail to notice the empty bottle.

The potential hazard of air embolism can be avoided only by ensuring that the point where all the infusions come together, be it chamber, tap, or Y-connector, is at or below the level of the patient's central venous pressure.

STUART J TOVEY

Department of Nephrology,
Southmead Hospital,
Bristol

Poisoning with slow-release fenfluramine

SIR,—We wish to report the first death from ingestion of the 60-mg "slow-release" preparation of fenfluramine (Ponderax Pacaps, Servier). Deaths from earlier fenfluramine preparations have been reported previously.¹⁻⁴

A 5-year-old girl with a history of a febrile convulsion at 18 months told her mother that she had swallowed two Ponderax Pacaps half an hour earlier. Eventually 20 capsules (1200 mg, 70 mg/kg body weight) were found to be missing. On admission to hospital one hour after ingestion she was flushed, drowsy, dysarthric, and tremulous, with fine nystagmus. She could answer questions coherently. Her pulse and respiration rates were 116/min and 24/min respectively. Rectal temperature was 37°C.

Gastric lavage was carried out with the recovery of whitish material. Near the end of the procedure she had a tonic-clonic convulsion and was treated immediately with diazepam 5 mg intravenously. Convulsions ceased after two minutes, by which time she was limp and pulseless, with fixed, dilated pupils. After rapid endotracheal intubation, ventilation with 100% oxygen, and cardiac massage broad low-voltage complexes at 140/min were noted on the ECG. Despite resuscitative efforts, which included intravenous administration of sodium bicarbonate, calcium gluconate, 20% mannitol, and atropine, followed by intracardiac adrenaline and DC shock, she died some three hours after the ingestion of fenfluramine. Necropsy (by Dr R Nagle, Lothian and Borders police surgeon) showed mild congestion of the brain, slight pallor of the heart muscle, and whitish material in the stomach. Toxicological examination of the liver showed 2.4 mg of fenfluramine/100 g of liver.

In spite of the preparation being "slow-release" this history is typical of fenfluramine intoxication. Convulsions and cardiac arrhythmias have both been reported in fatal cases, the convulsions usually occurring first. In primates⁵ the parenteral administration of 50 mg/kg of fenfluramine causes convulsions and death some 90-240 min later. Cardiac arrhythmias and respiratory arrest occur terminally. Cardiac monitoring has been recommended by several authors and also the manufacturers of fenfluramine when toxicity is suspected. There have, however, been at least two fatal cases^{2,4} in which this precaution was taken.

In primates⁵ a lower convulsion threshold to various stimuli such as noise and handling has been observed. This suggests that syrup of ipecacuanha (*BPC*) used successfully in a child who had ingested 70 mg/kg fenfluramine⁶ might be preferable to gastric lavage. Other supportive measures used successfully in two 3-year-old children⁶ have included prophylactic intramuscular and intravenous diazepam. The reported deaths have occurred within three hours of ingestion and it has been inferred that recovery is likely if the child survives for four hours. Therapeutic doses of fenfluramine have been shown to cause mild hypoglycaemia,⁷